Across TCGA pan-cancer cohorts, S100A16 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated S100A16 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher S100A16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated S100A16 expression acts as an unfavorable survival marker.

HNSC and PRAD are the cancer types where S100A16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.069	0.768	<.001	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: S100A16 tumor-vs-normal RNA expression · all S100A16 data types